PROpel试验非BRCA突变亚组:奥拉帕利联合阿比特龙疗效与安全性
PROpel 3期试验非BRCA突变mCRPC亚组(n=693)事后探索性分析显示,奥拉帕利联合阿比特龙组中位rPFS为24.1个月,安慰剂联合阿比特龙组为19.0个月(HR 0.76,95%CI 0.61-0.94)。中位OS分别为39.6个月与38.0个月(HR 0.91,95%CI 0.73-1.13),HRQoL无显著差异,安全性与此前总体人群一致。
要点
- 非BRCA突变mCRPC中,奥拉帕利联合阿比特龙较安慰剂联合阿比特龙延长rPFS(24.1 vs 19.0个月,HR 0.76)。
- 中位OS为39.6 vs 38.0个月(HR 0.91,95%CI 0.73-1.13),置信区间跨1。
- HRQoL无显著差异,安全性与此前生物标志物未选择总体人群一致。
核心结论
- 在PROpel试验非BRCA突变mCRPC亚组中,奥拉帕利联合阿比特龙较安慰剂联合阿比特龙显示数值更长的rPFS,且无新安全性信号。
研究设计与样本
- PROpel为3期随机对照试验(NCT03732820),患者1:1随机接受奥拉帕利联合阿比特龙(联合泼尼松/泼尼松龙)或安慰剂联合阿比特龙(联合泼尼松/泼尼松龙)。
- 非BRCA突变定义为至少一项预设肿瘤组织或循环肿瘤DNA检测无阳性BRCA突变结果;该亚组共693例,分析为事后探索性分析。
主要发现
- 非BRCA突变亚组(n=693)研究者评估的中位rPFS为奥拉帕利联合阿比特龙组24.1个月 vs 安慰剂联合阿比特龙组19.0个月(HR 0.76,95%CI 0.61-0.94)。
- 中位OS分别为39.6个月 vs 38.0个月(HR 0.91,95%CI 0.73-1.13)。
- 其他事后探索性分析支持奥拉帕利联合阿比特龙的疗效发现;两治疗组HRQoL无显著差异。
- 安全性发现与此前生物标志物未选择总体人群一致。
临床怎么用
- 对于非BRCA突变的mCRPC患者,奥拉帕利联合阿比特龙可作为重要的新治疗选择予以考虑。
局限性
- 非BRCA突变亚组分析为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 3 PROpel trial (NCT03732820) demonstrated statistically significant and clinically meaningful radiographic progression-free survival (rPFS) benefit and numerically prolonged overall survival (OS) for olaparib plus abiraterone versus placebo plus abiraterone in first-line metastatic castration-resistant prostate cancer (mCRPC). The greatest benefit was in patients with a BRCA1 and/or BRCA2 mutation (BRCAm). OBJECTIVE: To inform treatment decision-making, we report analyses in the non-BRCAm subgroup in PROpel. DESIGN, SETTING AND PARTICIPANTS: Patients were randomized (1:1) to olaparib plus abiraterone with prednisone/prednisolone versus placebo plus abiraterone with prednisone/prednisolone. Patients without BRCAm were classified as having no positive BRCAm result by at least one prespecified tumour tissue or circulating tumour DNA test. Post hoc exploratory analyses included rPFS, OS, additional efficacy end points, health-related quality of life (HRQoL), and safety. RESULTS AND LIMITATIONS: Median investigator-assessed rPFS in the non-BRCAm subgroup (n = 693) was 24.1 mo for olaparib plus abiraterone versus 19.0 mo for placebo plus abiraterone (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.61-0.94). Median OS was 39.6 versus 38.0 mo, respectively (HR 0.91, 95% CI 0.73-1.13). Additional post hoc exploratory analyses support these efficacy findings for olaparib plus abiraterone. There was no significant difference in HRQoL between treatment arms. Safety findings were consistent with the overall biomarker-unselected population. CONCLUSIONS: Olaparib plus abiraterone provided numerically longer rPFS versus placebo plus abiraterone, with no new safety signals, in the non-BRCAm subgroup of patients with mCRPC in PROpel. Our findings support olaparib plus abiraterone as an important new treatment option for consideration in patients with non-BRCAm mCRPC.
引用
- Mehra N, Clarke NW, Armstrong AJ, et al. Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial. Eur Urol Oncol. 2026. PMID: 42833926. doi:10.1016/j.euo.2026.08.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。